Tenderwize
Retour à la recherche

Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 188 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or volume commitments; actual business may be low or zero.

The open-house agreements automatically cease if a competitive discount agreement for the same active substance is conc...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive discount agreements for pharmaceutical products containing Dexamethason and Gentamicin (ATC S01CA21) with AOK Bayern.
  • Agreements are identical for all participants, not individually negotiated.
Afficher le résumé complet

This is an open-house model (not a formal procurement procedure) by AOK Bayern for non-exclusive pharmaceutical discount agreements (Rabattverträge) for the active substance combination Dexamethason and Gentamicin (ATC S01CA21). Any eligible pharmaceutical company can enter into identical, non-negotiable agreements. The agreement period is from May 1, 2025 to April 30, 2027. No estimated contract value is provided.

Risques

No estimated value or volume commitments; actual business may be low or zero.

The open-house agreements automatically cease if a competitive discount agreement for the same active substance is conc...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • Must submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission via paper (two original copies) or electronically with qualified electronic signature (QES).

Les exigences peuvent être incomplètes.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house Arzneimittelrabattverträge Dexamethason und Gentamicin, ATC S01CA21

Non-exclusive discount agreements for Dexamethason and Gentamicin (ATC S01CA21). Eligible pharmaceutical companies can join the open-house model at any time until March 5, 2027. Agreements run from May 1, 2025 to April 30, 2027.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Apr 2025 - Apr 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Mar 05, 2027

Détails de la procédure

Date de publication
18 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
176568-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30